dc.creator | Chalkias A., Barreto E.F., Laou E., Kolonia K., Scheetz M.H., Gourgoulianis K., Pantazopoulos I., Xanthos T. | en |
dc.date.accessioned | 2023-01-31T07:42:30Z | |
dc.date.available | 2023-01-31T07:42:30Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1016/j.clinthera.2021.01.004 | |
dc.identifier.issn | 01492918 | |
dc.identifier.uri | http://hdl.handle.net/11615/72421 | |
dc.description.abstract | Purpose: The aim of the present article was to briefly summarize current knowledge about the immunomodulatory effects of general anesthetics and the possible clinical effects of this immunomodulation in patients with COVID-19. Methods: The PubMed, Scopus, and Google Scholar databases were comprehensively searched for relevant studies. Findings: The novel coronavirus causes a wide spectrum of clinical manifestations, with a large absolute number of patients experiencing severe pneumonia and rapid progression to acute respiratory distress syndrome and multiple organ failure. In these patients, the equilibrium of the inflammatory response is a major determinant of survival. The impact of anesthetics on immune-system modulation may vary and includes both pro-inflammatory and anti-inflammatory effects. Implications: Inhibition of the development of severe inflammation and/or the enhancement of inflammation resolution by anesthetics may limit organ damage and improve outcomes in patients with COVID-19. © 2021 Elsevier Inc. | en |
dc.language.iso | en | en |
dc.source | Clinical Therapeutics | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100437456&doi=10.1016%2fj.clinthera.2021.01.004&partnerID=40&md5=562200dd616c3d2a8dee6f055ec5d877 | |
dc.subject | anesthetic agent | en |
dc.subject | cisatracurium | en |
dc.subject | cytochrome P450 | en |
dc.subject | dexmedetomidine | en |
dc.subject | etomidate | en |
dc.subject | fentanyl | en |
dc.subject | midazolam | en |
dc.subject | opiate | en |
dc.subject | propofol | en |
dc.subject | rocuronium | en |
dc.subject | sufentanil | en |
dc.subject | suxamethonium | en |
dc.subject | anesthetic agent | en |
dc.subject | adaptive immunity | en |
dc.subject | adult | en |
dc.subject | adult respiratory distress syndrome | en |
dc.subject | arachidonic acid metabolism | en |
dc.subject | controlled study | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | critically ill patient | en |
dc.subject | disease exacerbation | en |
dc.subject | endotracheal intubation | en |
dc.subject | female | en |
dc.subject | histiocyte | en |
dc.subject | human | en |
dc.subject | immune system | en |
dc.subject | immunomodulation | en |
dc.subject | innate immunity | en |
dc.subject | male | en |
dc.subject | Medline | en |
dc.subject | meta analysis | en |
dc.subject | multiple organ failure | en |
dc.subject | noninvasive ventilation | en |
dc.subject | Review | en |
dc.subject | Scopus | en |
dc.subject | search engine | en |
dc.subject | systematic review | en |
dc.subject | complication | en |
dc.subject | critical illness | en |
dc.subject | drug effect | en |
dc.subject | immune system | en |
dc.subject | immunology | en |
dc.subject | inflammation | en |
dc.subject | pneumonia | en |
dc.subject | respiratory distress syndrome | en |
dc.subject | virology | en |
dc.subject | Anesthetics | en |
dc.subject | COVID-19 | en |
dc.subject | Critical Illness | en |
dc.subject | Humans | en |
dc.subject | Immune System | en |
dc.subject | Inflammation | en |
dc.subject | Pneumonia | en |
dc.subject | Respiratory Distress Syndrome | en |
dc.subject | Excerpta Medica Inc. | en |
dc.title | A Critical Appraisal of the Effects of Anesthetics on Immune-system Modulation in Critically Ill Patients With COVID-19 | en |
dc.type | other | en |